Mitochondrial Contribution to Inflammation in Diabetic Kidney Disease

Alla Mitrofanova 1,2,*, Antonio M. Fontanella 1,2, George W. Burke 3, Sandra Merscher 1,2 and Alessia Fornoni 1,2

1 Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
2 Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA
* Correspondence: a.mitrofanova@miami.edu; Tel.: +1-305-247-2577

Abstract: Diabetes is the leading cause of chronic kidney disease worldwide. Despite the burden, the factors contributing to the development and progression of diabetic kidney disease (DKD) remain to be fully elucidated. In recent years, increasing evidence suggests that mitochondrial dysfunction is a pathological mediator in DKD as the kidney is a highly metabolic organ rich in mitochondria. Furthermore, low grade chronic inflammation also contributes to the progression of DKD, and several inflammatory biomarkers have been reported as prognostic markers to risk-stratify patients for disease progression and all-cause mortality. Interestingly, the term “sterile inflammation” appears to be used in the context of DKD describing the development of intracellular inflammation in the absence of bacterial or viral pathogens. Therefore, a link between mitochondrial dysfunction and inflammation in DKD exists and is a hot topic in both basic research and clinical investigations. This review summarizes how mitochondria contribute to sterile inflammation in renal cells in DKD.

Keywords: DKD; inflammation; mitochondria; innate immunity; podocyte; tubule cells

1. Introduction

Chronic kidney disease (CKD) is a worldwide health issue with an estimated prevalence of 16% [1]. CKD is characterized by proteinuria, reduced glomerular filtration rate and progressive glomerular, tubular and interstitial damage. Glomeruli play an important role in filtering blood, and glomerular injury leads to the development of various glomerular diseases, including diabetic kidney disease (DKD) which is the most common single cause of end stage kidney disease in the United States [2]. Currently, the pharmacological management of DKD includes the use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in association with sodium–glucose cotransporter 2 inhibitors or non-steroidal mineralocorticoid receptor antagonists [3]. However, these interventions only partially stabilize kidney function [4], and further work is needed to elucidate the precise pathological mechanisms contributing to DKD development and progression.

Among other factors that contribute to the development and progression of glomerular diseases, inflammation, oxidative stress, and immune system activation have recently gained more attention. Inflammation is generally initiated by the activation of pattern recognition receptors (PRRs) that are expressed by immune and non-immune cells [5]. Besides infection-associated molecules, PRRs may be activated by endogenous molecules called damage-associated molecular patterns (DAMPs), which include nucleic acids, ATP and proteins. However, DAMPs contribute to the initiation of inflammatory responses in a state of cellular stress or death when perturbations in permeability of various cellular compartments occur. Therefore, mitochondria, as the evolutionary remnants of ancestral alphaproteobacteria [6], have an important role in controlling cellular inflammation. Moreover, mitochondria are complex organelles and play a significant role in regulating...
cell death by apoptosis or necrosis [7]. All these facts indicate mitochondria are a unique platform for the redistribution of DAMPs and the activation of PRRs.

Considering that the kidney and heart [8] are the two organs that require the highest mitochondrial content to enable proper function, the role of mitochondria in the development and progression of kidney diseases, including DKD, has become the focus of recent studies [9–11]. Podocytes are terminally differentiated epithelial cells that play a key role in the glomerular filtration and are target cells in diabetes-associated kidney injury. Podocytes are highly dynamic and require substantial amounts of energy to maintain proper organization of cytoskeletal and extracellular matrix proteins and for foot processes remodeling [12]. Interestingly, under normal physiological conditions, tubular cells and podocytes use different substrates to produce energy: tubular cells rely on fatty acid β-oxidation, while podocytes preferentially use glucose [13–16]. However, under disease conditions, such as DKD, podocytes switch their energy substrate to fatty acids, in association with a reduced expression of many glycolytic enzymes, while the expression of β-oxidation enzymes is up-regulated [17]. Although podocytes contain a relatively small number of mitochondria, their contribution to podocyte injury in the state of a cellular stress becomes more obvious, as abnormalities in mitophagy, a mechanism of mitochondrial specific autophagy, and caspase activation can be observed. In this review, we discuss the mechanisms through which mitochondria control the intracellular inflammatory responses in podocytes and we will discuss potential areas that need future investigation.

2. Mitochondrial Regulation of Inflammation

2.1. cGAS-STING Signaling

Cyclic GMP-AMP (cGAS) is a nuclear and cytosolic protein that senses the presence of double-stranded DNA in the cytosol leading to the formation of a second messenger, cyclic GMP-AMP (cGAMP) and activation of stimulator of interferon genes (STING). STING activation culminates in the recruitment of different kinases: TANK-binding kinase 1 (TBK1), mitogen-activated protein kinase kinase kinase 14 (MAP3K14 or NIK) and heterotrimeric IκB kinase (IKK), which, in turn, promote interferon regulatory factor 3 (IRF3), non-canonical nuclear factor kappa B (NF-κB) and canonical NF-κB, respectively. As a result, IRF3 activation results in type I interferon responses, which are usually mainly associated with antiviral and anticancer effects [18], while NF-κB activation may lead to a broad spectrum of effects [19–21]. A common concept suggests that STING predominantly localizes to the outer membrane of the endoplasmic reticulum, but some studies report the presence of STING in the mitochondrial membrane [22,23].

While the cGAS-STING pathway was originally discovered in the context of the innate immunity response to infections and cancer [24–26], it is clear that the STING pathway is more than just important in pathogen detection; it also plays a significant role in the detection of self-DNA released from damaged mitochondria (Figure 1), dying cells or tumor cells. Thus, activation of the cGAS-STING in response to the presence of mitochondrial DNA (mtDNA) present in the cytosol of cells has been shown in mouse models of renal fibrosis [27]. Our studies suggest that STING phosphorylation is increased in the db/db mouse model of DKD at baseline and that pharmacological STING inhibition protects from DKD progression [28,29]. Interestingly, induction of STING itself in wildtype mice resulted in proteinuria and podocyte foot process effacement in studies [28,29]. Using eNOS db/db mice and rats with type 2 diabetic nephropathy, others demonstrated increased activity of the cGAS-STING pathway [30]. In patients with DKD, the presence of plasma and urinary mtDNA was recently recognized as a potential marker of early DKD progression [31–34]. However, the mechanisms of mtDNA escape into the cytosol remain elusive.
mtDNA is particularly vulnerable to damage. Given the fact that mtDNA resides in close proximity to mitochondrial reactive oxygen species (mtROS), oxidative lesions often cause mtDNA damage via DNA strand breakage or nucleotide base oxidation. In DKD, chronic hyperglycemia disrupts the bioenergetic balance, which results in mtROS production and oxidative mtDNA damage as shown in studies of glomeruli from DBA/2J mice [35] and streptozotocin (STZ)-induced DKD rats [36]. Additionally, in STZ-induced DKD mice mitochondrial biogenesis is reduced due to decreased mRNA expression of peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α), nuclear respiratory factor 1 (NRF-1) and mitochondrial transcriptional factor A (TFAM) [37]. Interestingly, decreased expression of TFAM has been reported in renal tissues from patients with CKD stage 4, while TFAM knockdown in mice results in mtDNA leakage into the cytosol and activation of the cGAS-STING pathway [27]. Release of mtDNA into the cytosol can cause activation of the proapoptotic pore-forming proteins BCL2-associated X, apoptosis regulator (BAX) and BCL2 antagonist/killer 1 (BAK1) as discussed below. A link between lipotoxicity and

Figure 1. Mitochondrial DNA triggers pro-inflammatory signaling pathways. Mitochondrial DNA (mtDNA) can activate three major pro-inflammatory signaling pathways that include endosomal toll-like receptor 9 (TLR9) with activation of nuclear factor κB (NF-κB), the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon gene (STING) with activation of interferon type I (INF-I) and cytosolic NLR family pyrin domain containing 3 (NLRP3) inflammasome activation with induction of caspase-1-dependent apoptosis. ER—endoplasmic reticulum; cGAMP—2′3′-cyclic GMP-AMP.
mtDNA release into the cytosol followed by activation of the cGAS-STING pathway was recently reported in db/db mice on a high fat diet [38].

In summary, an abundant literature shows the ability of mtDNA to activate the cGAS-STING signaling pathway in the kidney, thereby driving an inflammatory response in DKD.

2.2. RLR Signaling

The RIG-I like receptor (RLR) signaling pathway is another inflammatory pathway that can be stimulated by mitochondria (Figure 1). Unlike the cGAS-STING pathway, the RLR pathway is activated by foreign, altered, or ectopic RNA [39]. It has been shown that mitochondrial RNA (mtRNA) can be released into cytosol in a state of reduced polyribo nucleotide nucleotidyltransferase 1 (PNPT1) expression, leading to mtRNA degradation, and activation of RLR melanoma differentiation-associated protein 5 (MDA5) [40]. Interestingly, mtDNA double-strand breaks have been shown to contribute to BAX-BAK1-mediated mtRNA release into cytosol with further activation of RIG-I, but not MDA5 [41]. However, the mechanisms leading to the differential activation of RIG-I versus MDA5 by mtRNA species remain to be discovered.

Notably, a recent study of patients with type 2 diabetes revealed a specific serum RNA signature in patients with DKD when compared to patients with diabetes and no DKD, where downregulation of four mitochondrial messenger RNAs (ATP6, ATP8, COX3 and ND1) was found to correlate with serum creatinine and estimated glomerular filtration rate [42]. A genome-wide association study analysis of patients with type 1 diabetes (n = 19,406) also revealed the association of RIG-I/MDA5 and interferon alpha beta gene set [43].

2.3. Inflammasome Signaling

The inflammasome comprises a class of signalosomes in innate immunity that promote inflammation and induce an inflammatory form of programmed cell death, called pyroptosis. Early studies have shown that cytosolic mtDNA can also drive the activation of inflammasomes [44], specifically of the inflammasome that contains nucleotide-binding domain-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) as a sensing component (Figure 1). NLRP3 assembles the inflammasome through oligomerization with apoptosis-associated speck-like protein (ASC) to elicit robust caspase 1 (CASP1) activation and production of interleukins 1β (IL-1β) and 18 (IL-18). Oxidized mtDNA release into the cytosol upon mitochondrial dysfunction has been shown to activate the NLRP3 inflammasome [45], and a feedforward loop was identified in which inflammasome activation facilitates mtDNA release via mtROS production [46]. Besides the mtROS-associated NLRP3-ASC-driven mtDNA escape into the cytosol, a physical interaction between NLRP3 and thioredoxin-interacting protein (TXNIP), a nuclear protein that controls the cellular redox state, may induce mitochondrial damage and mtDNA leakage [47]. However, ROS inhibitors seem to disrupt inflammasome priming, i.e., the synthesis of inflammasome components, but not its activation [48]. In line with this notion, recent studies showed that NLRP3 inflammasome activation depends on the mitochondrial electron transport chain [49], and that cytosolic oxidized mtDNA serves as the ultimate NLRP3 ligand [50]. Of note, mitochondrial damage per se does not trigger NLRP3 signaling if priming is omitted (reviewed in [51]). Moreover, NLRP3 inflammasome activation fails under conditions of TFAM deficiency [50]. However, mtDNA has been shown to also activate inflammasomes that use the absence of melanoma 2 (AIM2) as a sensing component [52]. Interestingly, while oxidized DNA seems to activate NLRP3 inflammasomes [45], AIM2-containing counterparts are suggested to recognize non-oxidized DNA [50].
Persistent and aberrant NLRP3 signaling underlies many chronic diseases, including type 1 and type 2 diabetes, while NLRP3 deficiency has been shown to protect against injury, irrespective of the renal cell type [53,54]. mtDNA seems to be one of the main triggers of NLRP3 activation in streptozotocin-induced diabetic [55,56] and in high fat diet mice [57]. Using primary renal tubular epithelial cells and unilateral ureteral obstruction (UUO) mice, a recent study demonstrated that peroxisomal proliferator-γ coactivator-1α (PGC-1α) ameliorates NLRP3 inflammasome-associated renal fibrosis via the modulation of mitochondrial dynamics [58]. NLRP3 activation also contributes to DKD progression as shown in a study demonstrating that podocyte-specific Nlrp3 or caspase-1 deficiency resulted in protection from DKD [59]. In contrast, another group reported that using an NLRP3-specific inhibitor, MCC950, did not confer renoprotective effects using streptozotocin-induced diabetic mice as it did not reduce renal inflammation (glomerular accumulation of CD68 positive cells), mesangial expansion and glomerulosclerosis [60]. However, an earlier study reported that MCC950 lowered fibrosis, renal inflammation and provided protection from kidney failure in a model of oxalate nephropathy [61]. Less is known about the role of AIM2 inflammasomes in diabetes and DKD development. It has been shown that AIM2 inflammasomes directly interact with apoptosis-associated speck-like protein and contribute to the development of many human diseases, including type 2 diabetes, where cell-free mtDNA has been shown to activate AIM2 inflammasomes [62].

In summary, mtDNA is a major DAMP for inflammasome activation that contributes to chronic kidney disease development and progression. Moreover, NLRP3 and AIM2 may represent a potential therapeutic target to ameliorate DKD-associated podocyte and tubular injury.

2.4. TLR Signaling

Toll-like receptor (TLR) signaling plays a key role in the innate immune system by recognizing pathogen-associated molecular patterns (PAMPs) leading to the activation of NF-κB and interferon production. The TLR family comprises 10 members in humans (TLR1-TLR10) and 12 members in mice (TLR1-TLR12). TLRs are located on the cell plasma membrane, except for TLR3, TLR7, TLR8 and TRL9, which are found in intracellular vesicles where they sense the nucleic acids inside a cell. Early studies showed that naked as well as protein-bound mtDNA has been shown to activate TLR9 (Figure 1) and advanced glycosylation end product-specific receptor (RAGE) [63,64]. Other studies demonstrated that treatment in vitro or in vivo with mtDNA results in increased levels of TLR9, NF-κB and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκB-α) in different tissues [65–67]. De novo TLR9 expression has been shown in podocytes of some patients with glomerular diseases [68–71], suggesting that endogenous mtDNA serves as a ligand and may facilitate podocyte apoptosis [72]. In a model of acute kidney injury, absence of TLR9 reduced mtDNA-mediated kidney injury [73]. In DKD, the expression of TLR2, TLR4, TLR5, TLR7, TLR8 and TLR9 has been described, but TLR2 and TLR4 are the two most extensively studied receptors (reviewed in [74]). Sparse studies on TLR3 and TLR9 in DKD suggest that in the ApoE-/- streptozotocin-induced mouse model of DKD, TLR3 and TLR9 are activated in the kidney [75]. Similarly, enhanced expression of TLR3 was reported in tubules from patients with DKD [76]. Nevertheless, no data are available that would connect activation of TLR3 and TLR9 in DKD with the release of mtDNA into the cytosol, which may be the subject of future studies.
2.5. NF-κB Signaling

Nuclear factor-κB (NF-κB) represents a family of transcription factors which consists of five structurally related members (NF-κB1, NF-κB2, RelA, RelB and c-Rel) and regulates a large array of genes involved in the regulation of the immune and inflammatory responses. The activation of the NF-κB involves two major signaling pathways: (1) in the canonical pathway, NF-κB responds to diverse stimuli, including cytokine receptors, PRRs, TNF receptors, T-cell and B-cell receptors [77]; (2) in the noncanonical (alternative) pathway, NF-κB selectively responds to specific ligands such as lymphotoxin beta receptor (LTβR), tumor necrosis factor receptor superfamily member 13C (TNFRSF13C or BAFFR), CD40, or RANK [78]. Functionally, the canonical NF-κB pathway is involved in almost all aspects of the immune response, while the noncanonical NF-κB appears to be involved in the regulation of specific functions of the adaptive immune system. Interestingly, the suppression of inhibitor of apoptosis (IAP) proteins by the cytosolic mitochondrial protein SMAC shifts NF-κB signaling from the canonical to the noncanonical pathway upon stabilization of mitogen-activated protein kinase kinase kinase 14 (MAP3K14), and this process is orchestrated by BAK1-BAX oligomers [79].

A recent study addressing the role of NF-κB in DKD showed an activation of the NF-κB pathway in diabetic rats that progress to DKD, whereby inflammation was restricted to the glomerular compartment with intense glomerular macrophage infiltration [80]. Earlier studies also confirmed modest activation of the glomerular NF-κB signaling pathway in streptozotocin treated rats as early as one month after the induction of diabetes [81], while in patients with type 2 diabetes, NF-κB activation was mainly detected in cortical tubular epithelial cells and, to a lesser extent, in some glomeruli [82]. Similarly, in patients with type 1 diabetes and DKD, p65 positive glomeruli and inflammation in the area of the renal interstitium were found [80]. High glucose has also been shown to induce NF-κB activation and upregulation of proinflammatory cytokines in human proximal tubular epithelial cells [83] and in podocytes [84]. Interestingly, long-term (12 months) NF-κB inhibition in diabetic rats using pyrrolidine dithiocarbamate resulted in reduced IL-6 production and prevented the development of glomerulosclerosis and loss of podocyte integrity in one study [80]. Therefore, the canonical pathway seems to be the prevalent NF-κB activation pathway in DKD (Figure 2). However, the exact mechanisms leading to NF-κB activation in DKD remain unclear and require further investigation.

To make the picture even more complicated, NF-κB subunits (IkBα, p65) and NF-κB pathway proteins (IKKα, IKKβ and IKKγ) are present in the inner mitochondria matrix [85–88]. Collectively, these studies suggest that NF-κB can non-specifically bind mtDNA sequences and regulate mRNA expression of a variety of target genes. Recent studies also demonstrated that NF-κB is involved in mitochondrial fission [89], regulation of BAX mediated cytochrome c release to control apoptosis [90], organization of the energy metabolism network by controlling the balance between glycolytic utilization and mitochondrial respiration [42,91], and in controlling respiratory chain gene expression including the expression of COXI, COXIII and CytB [86,92,93]. Moreover, NF-κB p62 induction restricts NLRP3 inflammasome activation via the elimination of damaged mitochondria [94].
Figure 2. Mitochondrial contribution to DKD associated kidney damage. Generation of mitochondrial reactive oxygen species (mtROS), escape of mitochondrial RNA (mtRNA) and mitochondrial DNA (mtDNA) into cytosol, production of oxidized mitochondrial DNA (oxmtDNA) and abnormalities in mitophagy lead to activation of major pro-inflammatory signaling pathways, pyroptotic, apoptotic and ferroptotic cell death. Abbreviations: APAF1—apoptotic pepdidase activating factor 1; BAK—Bcl2 homologous antagonist/killer; BAX—Bcl2-associated X protein; BCL2—B-cell lymphoma 2; BID—BH3 interacting-domain death agonist; CASP1—caspase 1; CASP3—caspase 3; CASP9—caspase 9; cGAS—cyclic GMP-AMP synthase; cGAMP—2′,3′-cyclic GMP-AMP; Cyt C—cytochrome c; ER—endoplasmic reticulum; IL-1—interleukin 1; IL-18—interleukin 18; IMM—inner mitochondrial membrane; INF-I—interferon type I; IRF3—interferon regulatory factor 3; LC3—microtubule-associated protein 1A/1B-light chain 3; MDA5—melanoma differentiation-associated protein 5; NF-kB—activation of nuclear factor κB; NLRP3—NLR family pyrin domain containing 3; NRF1—nuclear respiratory factor 1; OMM—outer mitochondrial membrane; PGC-1α—peroxisome proliferator-activated receptor-γ coactivator-1α; PINK1—PTEN induced kinase 1; PUMA—p53 upregulated modulator of apoptosis; RIG-I—retinoic acid-inducible gene I; STING—stimulator of interferon gene; TBK1—TANK binding kinase 1; TFAM—mitochondrial transcription factor A; TLR9—toll-like receptor 9; Ub—ubiquitin.
3. Mitochondrial Regulation of Cell Death

3.1. BAX-BAK1 Signaling

One of the mechanisms of mtDNA release in the course of mitochondrial outer membrane permeabilization involves the proapoptotic pore-forming proteins BCL2-associated X, apoptosis regulator (BAX) and BCL2 antagonist/killer 1 (BAK1). Under physiological conditions, mitochondrial outer membrane permeabilization is actively prevented by anti-apoptotic molecules BCL2, BCL2-like protein 1 (BCL2-L1, best known as BCL-XL) and MCL1. In the presence of an apoptotic stimulus such as BH3-interacting domain death agonist (BID) or BCL2-binding component 3 (BBC3, best known as PUMA), displacement of BAX and BAK1 from inhibitory interactions with BCL2, BCL-XL or MCL1 occurs. This, in turn, results in the translocation of cytochrome c from the mitochondrial intermembrane space into cytosol, assembly of an apoptotic peptidase-activating factor 1 (APAF1) and caspase 9 (CASP9)-containing molecular complex (known as apoptosome) and activation of CASP3 as one of the final steps in the apoptotic cascade. Intriguingly, BAX- and BAK1-independent mtDNA release have recently been described. Thus, proteolytically activated BID has been shown to form pores in mitochondria, independently of BAX and BAK1 in human cells [95]. In another study, mild mitochondrial stress did not result in mitochondrial outer membrane permeabilization and mtDNA release was associated with a voltage-dependent anion channel (VDAC)-dependent mechanism [96,97]. Even more interesting, different isoforms of VDAC have been shown to be associated with mitochondrial permeability transition (mPT) (reviewed in [98]), a regulated process of mitochondrial matrix swelling leading to abrupt loss of the impermeability of the inner mitochondrial membrane. This transition is mediated by the mitochondrial permeability transition pore (mPTP), a mitochondrial protein complex, by changing conformation and forming an IMM pore in response to some stimuli. The specific protein components and exact mechanisms of pore formation are poorly understood, but inhibition of mPTP opening by TRAP1 has been shown to protect against diabetic renal injury in STZ treated rats [99]. While VDAC isoforms are no longer considered to form part of the mPTP complex itself, its influence on mPT suggests a possible role as an mtDNA pore during mitochondrial swelling.

In the kidney, BAK1 knockout in a human podocyte cell line has been shown to diminish apolipoprotein L1 (APOL1) expression [100], a protein associated with CKD in populations with recent African ancestry. In another study, double knockout of BAX and BAK1 in proximal tubules resulted in decreased apoptosis in renal tubular cells and suppressed renal interstitial fibrosis in a model of unilateral urethral obstruction (UUO) [101]. Using a mouse model of acute kidney injury, BAX and BAK1 knockout was shown to attenuate renal tubular cell apoptosis and decrease cytochrome c release [102]. In support, high glucose-associated activation of BAX results in increased apoptosis of β-cells in mice on a high fat diet, while ablation of the Bax gene in islets improves diabetes [103]. Treatment of podocytes with high glucose (30 mM) also activates BAK1, BAX and cytochrome c, resulting in increased apoptosis [104]. Further, studies in podocytes isolated from a streptozotocin-induced mouse models of DKD and in the mouse podocyte clone 5 (MCP5) cell line revealed the anti-apoptotic protein BCL-2 as an important hub in the regulation of autophagy and apoptosis levels in the presence of high glucose [105]. In the same study decreased levels of BCL-2 were described in patients with diabetic nephropathy.

In summary, increasing studies support the idea that suppression of anti-apoptotic BCL-2 and activation of pro-apoptotic BAK1 and BAX are at the core of a complex intrinsic apoptotic pathway that contributes to DKD progression.

3.2. Cardiolipin

The mitochondrial unique phospholipid cardiolipin (CL), which is predominantly found in the inner mitochondrial membrane (IMM) [106], is crucial for biophysical properties of mitochondrial membranes, where it modulates energy production and participates in inflammation, mitophagy and apoptosis [107–111]. Intriguingly, the structural disruptions that accompany late stage regulated cell death generate mitochondrial fragments.
containing CL in the extracellular microenvironment, where CL promotes increased expression of MHC class I-like molecule CD1d on antigen presenting cells and results in the activation of a cardiolipin-specific population of T cells [112]. Thus, cardiolipin can promote inflammatory responses. In yeast cells, a 30% increase in the CL content results in physical modification of mitochondrial membranes affecting mtDNA stability via physical interaction between CL and mtDNA [113]. In liver, CL-mediated membrane remodeling also results in mtDNA aggregation and release [114].

In DKD, we reported increased CL peroxidation in db/db and ob/ob mice in association with mitochondrial dysfunction, while the inhibition of CL peroxidation with Elamipretide, which stabilizes CL at the inner mitochondrial membrane and inhibits cytochrome c mediated CL peroxidation, protected from DKD in vivo [9]. In another study using db/db mice, it was demonstrated that accumulation of total renal lysocardiolipin is associated with DKD, while the use of Elamipretide had renoprotective effects [115]. Interestingly, a role of innate immune complement component C5a in the cardiolipin remodeling and reduction of mitochondrial fatty acids metabolism in DKD has been demonstrated using mouse models of type 1 (Ins2-Akita mice, streptozotocin-induced diabetic mice and rats) and type 2 diabetes (db/db mice) [116]. While CL seems to be a significant player in DKD development and progression, it remains unclear if CL contributes to mtDNA escape into cytosol in renal cells.

3.3. Mitophagy

Mitophagy is a selective form of autophagy, where damaged or dysfunctional mitochondria undergo degradation and recycling. The PTEN-induced putative kinase protein 1 (PINK1)/E3 ubiquitin–protein ligase (Parkin) pathway is the most studied mechanism of mitophagy. Loss of mitochondrial membrane potential results in PINK1 accumulation at the outer mitochondrial membrane (OMM), phosphorylation (on Ser65) of pre-existing ubiquitin molecules and Parkin recruitment. In turn, PINK1-dependent phosphorylation of the ubiquitin-like domain of Parkin leads to the release of catalytic RING2 domain, which stabilizes Parkin in its functionally active state, followed by ubiquitination of other OMM proteins including voltage-dependent anion-selective channel (VDAC), mitochondrial Rho GTPase proteins (MIRO), mitofusin 1 (MFN1) and 2 (MFN2) [117]. Parkin promotes ubiquitination of LC3 on the lysine 63 (K63) and lysine 48 (K48) residues, whereby K48 ubiquitination initiates passive mitochondrial degradation, while K63 ubiquitination leads to the recruitment of the autophagy adaptors LC3/GABARAP (Figure 2). The underlying mechanisms, however, are not fully understood and remain to be further elucidated.

Other mechanisms of mitophagy have been also described. For example, the FUN14 domain containing 1 (FUNDC1) protein has a conserved LC3-interacting region. Under hypoxia or loss of mitochondrial membrane potential, dephosphorylation of Tyr18 and Ser13, mediated by the mitochondrial phosphatase PGAM family member 5 (PGAM5), and concomitant phosphorylation of Ser17 by ULK1 enhances FUNDC1 and LC3 interaction to promote mitophagy. Activity of PGAM5 is thereby controlled by BCL2-like 1 (better known as BCL-XL) [118]. FUNDC1 was found to interact with both the mitochondrial fission key factor dynamin 1 like (DRP1) and the inner membrane fusion regulator OPA1 to coordinate mitochondrial dynamics and mitophagy [119].

BCL2 interacting protein 3 (BNIP3) and NIX are proteins localized at the outer mitochondrial membrane and are also involved in stress sensing and hypoxia-induced mitophagy [120]. An increase in BNIP3 protein levels leads to the liberation of Beclin 1 from BCL2 apoptosis regulator and BCL-XL sequestration to initiate mitophagy and prevent mtROS production and cell death. Both BNIP3 and NIX interact with LC3 to further enhance autophagosomal recruitment to mitochondria [121].

Impaired mitophagy is recognized as a hallmark of human DKD and of rodent models of DKD. In patients with DKD and in rats with streptozotocin-induced DKD, activation of thioredoxin interacting protein (TXNIP) under hyperglycemic conditions was shown to cause accumulation of autophagosomes and reduced autophagic clearance in tubular...
cells [122]. Renal tubular epithelial cells treated with high glucose and biopsies from DKD patients have shown reduced levels of mitophagy [123]. Diabetic db/db mice were found to have decreased expression levels of mitochondrial PINK1, Parkin, LC3-II, Beclin-1 and Atg5, all the markers of impaired mitophagy [124]. Progression of DKD is associated with gradual decrease of Parkin expression in renal tubular epithelial cells of patients with DKD (n = 149), and overexpression of Parkin reduces inflammation and improves renal function in streptozotocin-induced diabetic mice [125]. Similar, reduced PINK1/Parkin mitophagy was reported under high glucose conditions in HK-2 cells and in the streptozotocin-induced mouse model of DKD [10,126,127], in proximal tubular cells [122] and in podocytes and db/db mouse model of DKD [128] and in rats on a high fat diet [129]. In contrast, some studies report an abnormal activation of PINK1/Parkin mediated mitophagy in db/db mice [130,131]. As no differences in the genetic background of the animals used in these studies have been noticed, more detailed investigations are needed to explain the opposite results observed in the activation pattern of the PINK1/Parkin mediated autophagy.

Interestingly, involvement of the PI3K/ AKT/ mTOR signaling pathway, a major intracellular network that regulates cell proliferation and life cycle and in the regulation of autophagy in glomerular mesangial cells have been shown in several studies [129,132–136], suggesting an important role of autophagy in renoprotection. As in other kidney cell types, decreased levels of LC3-II, PINK1 and Parkin have been reported in glomerular endothelial cells under high glucose treatment [128]. The use of different compounds to regulate mitophagy in DKD has been widely reported and is summarized in Table 1.

Table 1. Mitophagy modulators in experimental models of DKD.

| Compound | Target | Model | Phenotype | Ref. |
|----------|--------|-------|-----------|------|
| Metformin | AMPK   | HFD mice | ↓ mtROS production | ↑ PINK1 and Parkin protein levels | ↑ LC3-II and Atg5 levels | [137] |
| Mitotempo | mtROS  | HG-treated mouse primary RTECs | ↓ mtROS production | ↓ oxidative stress | ↓ caspase-3 expression | ↑ Δψm | [123] |
| MitoQ    | Nrf2/PINK1 | db/db mice | Restored mitochondrial morphology | ↓ mtROS production | ↓ BAX mediated apoptosis | [10] |
| D-glucarate | MIOX  | HK-2 cells STZ mice | ↑ mitophagy via PINK1 and Parkin | [128] |
| CoQ10    | Nrf2   | HG-treated mGECs | ↑ mitophagy and LC3-II levels | ↓ p62 | [129] |
| Triptolide | PTEN/AKT/mTOR | HFD rats | ↑ mitophagy and LC3 levels | ↑ mTOR production | ↑ autophagy and LC3-II levels | ↓ p62 | [139] |
| Palmitic acid | PINK1/Parkin | HFD rats | ↑ mitophagy and LC3 levels | ↑ mTOR production | ↑ apoptosis | [133] |
| Progranulin | CAMKK-AMPK | HFD rats STZ mice | ↑ autophagy and LC3 levels | [127] |
| APF      | mTOR/PINK1/Parkin | HG-treated RMCs STZ mice | ↑ mitophagy via PINK1 and Parkin | [136] |
| Icariin  | Nrf2/GPER | STZ rats HG-treated hGMCs | ↓ superoxide anion | ↑ antioxidant enzymes activity | [133] |
| Ursolic acid | PI3K/AKT/mTOR | HG-treated rGMCs | ↑ LC3 levels | ↑ PTEN mRNA and protein expression | [135] |
3.4. Pyroptosis and Ferroptosis

Pyroptosis is a caspase-1-dependent form of cell death that is triggered by proinflammatory signals from microbial infections and non-infectious stimuli. While caspase-1-dependent cell death is mediated by caspases, it was initially not distinguished from apoptosis. However, it has become clear that the mechanism, characteristics and outcome of caspase-1-dependent cell death are distinct from apoptosis [140]. Pyroptosis can also be initiated by non-canonical inflammasome pathway via activation of caspase-11 in mice and caspase-4 in humans and the cleavage of gasdermin D (GSDMD) [141]. Notably, TLRs, RLRs and NLRs have been shown to mediate pyroptosis, whereby NLRP3 is the most connected molecule to pyroptosis as reviewed elsewhere [142,143]. Caspase-4/11 and GSDMD-dependent pyroptosis contribute to podocyte loss and DKD progression [144]. In high glucose treated podocytes and streptozotocin-induced DKD mice, NLRP3-mediated upregulation of GSDMD and mtROS/NLRP3 dependent pyroptosis have been described [145]. Interestingly, in membranous nephropathy, another type of glomerular disease, complement-induced pyroptosis was shown to contribute to podocytes injury [146]. Intriguingly, cleavage of the amino-terminal sequence of GSDMD induces mitochondrial outer membrane permeabilization [147–149], but the mechanism needs to be further elucidated.

Ferroptosis is a novel form of programmed cell death derived by the iron-dependent peroxidation of lipids through the cysteine/glutamate antiporter Xc- (xCT) and glutathione peroxidase 4 (GPX4)-dependent mechanisms. In the state of high fructose, significant upregulation of mitochondrial single-strand DNA-binding protein 1 (SSBP1) has been shown to contribute to podocyte injury via activation of the transcriptional factor p53 and ferroptosis [150]. In the mouse glomerular podocyte MPC5 cell line, high glucose was found to induce ferroptosis via suppression of peroxiredoxin 6 (Prdx6), an antioxidant that reduces oxidative stress, and specificity-protein 1 (Sp1), zinc finger family transcription factor, regulating cell survival and proliferation in many ways [151]. Interestingly, a significant role of VDAC, the mitochondrial transmembrane channel that transports ions and metabolites, plays an important regulatory role in ferroptosis via ROS- and nitric oxide-dependent signaling pathways [152]. Moreover, lipid metabolism, which is dysregulated in DKD, is closely associated with ferroptosis, and phosphatidylethanolamine is the key phospholipid that induces ferroptosis in cells. Lipid induced ROS accumulation is another mechanism leading to ferroptosis, and mitochondria have been shown to contribute to lipid induced ROS accumulation in mouse embryonic fibroblasts [153], suggesting a crucial role of mitochondria in ferroptosis. A correlation between iron, lipid peroxidation and ferroptosis associated marker acyl-CoA synthetase long-chain family member 4 (ACSL4) was established in renal tubular cells of db/db and streptozotocin-induced DKD mice [154]. Ferroptosis may also contribute to DKD development via suppression of nuclear factor erythroid factor 2-related factor 2 (NRF2) [155], a critical transcriptional factor involved in the regulation of many cellular processes. Transforming growth factor β (TGFβ)-stimulated

### Table 1. Cont.

| Compound | Target | Model | Phenotype | Ref. |
|----------|--------|-------|-----------|------|
| Astragaloside IV | Not specified | db/db mice | ↓ mitophagy via PINK1 and Parkin | [130] |
| HDD | Not specified | db/db mice | ↓ renal DRP1, FIS1, MFF expression | [131] |

Abbreviations: AKT—protein kinase B; AMPK—AMP-activated protein kinase; APF—Astragalus mongholicus Bunge and Panax notoginseng F.H. Chen formula; CAMKK—calcium/calmodulin-dependent protein kinase; DRP1—dynamin-related protein 1; FIS1—mitochondrial fission 1 protein; hGMCs—human glomerular mesangial cells; rGMCs—rat glomerular mesangial cells; mGEC—murine glomerular endothelial cells; GPER—G protein-coupled estrogen receptor; HDD—Huangqi-Danshen decoction; HFD—high fat diet; HG—high glucose; HK-2—human kidney 2 cells; MFF—mitochondrial fission factor; MIOX—Myo-inositol oxygenase; mTOR—mammalian target of rapamycin; PT—proximal tubular cells; PTEN—phosphatase and tensin homolog; RMCs—renal mesangial cells; RTECs—renal tubular epithelial cells; STZ—streptozotocin; Δψm—mitochondrial membrane voltage potential.
tubular cells also exhibit increased levels of ferroptosis, which were shown to be reduced by ferrostatin-1, the ferroptosis inhibitor [156].

Thus, there remains no doubt that pyroptosis and ferroptosis contribute to podocyte death in mouse models of DKD, but the exact mechanistic pathways have not yet been identified. Moreover, whether ferroptosis contributes to the progression of DKD in patients with diabetes remains to determined.

4. Conclusions

Although mitochondria are master regulators of inflammation and cell death in the diabetic kidney (Figure 2), additional research is needed to address many questions. Thus, well-established mechanistic links between inflammatory responses directed by mitochondria and DKD development and progression are often missing and remain to be uncovered. Moreover, additional work is needed to characterize the roles of autophagy and apoptotic caspases in the regulation of inflammation driven by mitochondrial damage associated molecular pattern, with special attention to the roles of other cellular processes associated with mitophagy in different kidney cells in DKD. Additionally, the key molecular details, such as the interaction of mtDNA with inflammasomes or of mtDNA depletion and altered cellular biogenesis and oxidative balance remain to be clarified. Surprisingly, little progress has been made over the past 10 years in uncovering the specific roles of the important transcriptional factor NF-κB in mitochondrial function and data revealing the presence of NF-κB in mitochondria from renal cells are missing. Therefore, the discovery of a role for NF-κB signaling in mitochondria in DKD may open new therapeutic perspectives. Additionally, the levels of ROS have not been carefully measured in podocytes, and applying a single-cell RNA sequence approach should be used to eliminate this issue. Lastly, it remains necessary to continue the investigation of mitochondrial function under physiological and pathological conditions which will ultimately lead to the discovery of novel therapeutics to prevent, reverse and treat DKD and, possibly, other diabetic complications.

Author Contributions: Writing—original draft preparation, A.M. and A.M.F.; figure drawings, A.M.; writing—review and editing, G.W.B., S.M. and A.F.; visualization, A.M.; supervision, A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Carl W. Gottschalk Research Scholar Grant, American Society of Nephrology (GR018262) and by Chernowitz Medical Research Foundation (GR021608). S.M. and A.F. are supported by the NIH grants R01DK104753, R01CA227493. A.F. is supported by NIH grants U54DK083912, UM1DK100846, U01DK116101 and UL1TR002736 (Miami Clinical Translational Science Institute). A.F. and S.M. are supported by Aurinia Pharmaceuticals Inc. and Boehringer Ingelheim.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.; Yang, C.W. Chronic kidney disease: Global dimension and perspectives. *Lancet* 2013, 382, 260–272. [CrossRef]
2. USRDS. 2021 USRDS Annual Data Report: Epidemiology of kidney disease in the United States; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2021.
3. De Boer, I.H.; Khunti, K.; Sadusky, T.; Tuttle, K.R.; Neumiller, J.J.; Rhee, C.M.; Rosas, S.E.; Rossing, P.; Bakris, G. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int.* 2022, 102, 974–989. [CrossRef]
4. Skrabic, R.; Kumric, M.; Vrdoljak, J.; Rusic, D.; Skrabic, I.; Vilovic, M.; Martinovic, D.; Duplancic, V.; Tincovic Kurir, T.; Bozic, J. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. *Biomedicines* 2022, 10, 2458. [CrossRef]
5. Kroemer, G.; Galassi, C.; Zitvogel, L.; Galluzzi, L. Immunogenic cell stress and death. *Nat. Immunol.* 2022, 23, 487–500. [CrossRef]
6. Roger, A.J.; Muñoz-Gómez, S.A.; Kamikawa, R. The Origin and Diversification of Mitochondria. *Curr. Biol.* 2017, 27, R1177–R1192. [CrossRef]
7. Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W.; et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ.* 2018, 25, 486–541. [CrossRef]
8. Wang, Z.; Ying, Z.; Bosy-Westphal, A.; Zhang, J.; Schautz, B.; Later, W.; Heymsfield, S.B.; Müller, M.J. Specific metabolic rates of major organs and tissues across adulthood: Evaluation by mechanistic model of resting energy expenditure. *Am. J. Clin. Nutr.* 2010, 92, 1369–1377. [CrossRef]

9. Ducasa, G.M.; Mitrofanova, A.; Mallela, S.K.; Liu, X.; Molina, J.; Sloan, A.; Pedigo, C.E.; Ge, M.; Santos, J.V.; Hernandez, Y.; et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. *J. Clin. Investig.* 2019, 129, 3387–3400. [CrossRef]

10. Zhan, M.; Usman, I.M.; Sun, L.; Kanwar, Y.S. Disruption of Renal Tubular Mitochondrial Quality Control by Myo-Inositol Oxidase in Diabetic Kidney Disease. *Am. J. Soc. Nephrol.* 2015, 26, 1304–1321. [CrossRef]

11. Na, K.R.; Jeong, J.Y.; Shin, J.A.; Chang, Y.K.; Suh, K.S.; Lee, K.W.; Choi, D.E. Mitochondrial Dysfunction in Podocytes Caused by CRIF1 Deficiency Leads to Progressive Albuminuria and Glomerular Sclerosis in Mice. *Int. J. Mol. Sci.* 2021, 22, 4827. [CrossRef]

12. Galvan, D.L.; Green, N.H.; Danesh, F.R. The hallmarks of mitochondrial dysfunction in chronic kidney disease. *Kidney Int.* 2017, 92, 1051–1057. [CrossRef]

13. Abe, Y.; Sakairi, T.; Kajiyama, H.; Shrivastav, S.; Beeson, C.; Kopp, J.B. Bioenergetic characterization of mouse podocytes. *Am. J. Physiol. Cell Physiol.* 2010, 299, C464–C476. [CrossRef]

14. Fink, B.D.; Herlein, J.A.; O'Malley, Y.; Sivitz, W.I. Endothelial cell and platelet bioenergetics: Effect of glucose and nutrient composition. *PLoS ONE* 2012, 7, e39430. [CrossRef]

15. Czajka, A.; Malik, A.N. Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells: Implications for diabetic nephropathy. *Redox Biol.* 2016, 10, 100–107. [CrossRef]

16. Brinkkoetter, P.T.; Bork, T.; Salou, S.; Liang, W.; Mizi, A.; Özel, C.; Koehler, S.; Hagmann, H.H.; Ising, C.; Kuczkowski, A.; et al. Anaerobic Glycolysis Maintains the Glomerular Filtration Barrier Independent of Mitochondrial Metabolism and Dynamics. *Cell Rep.* 2019, 27, 1551–1566.e5. [CrossRef]

17. Imasawa, T.; Obre, E.; Bellance, N.; Lavia, J.; Imasawa, T.; Rigolther, C.; Delmas, Y.; Combe, C.; Lacombe, D.; Benard, G.; et al. High glucose reprograms human podocyte energy metabolism during differentiation and diabetic nephropathy. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 2017, 31, 294–307. [CrossRef]

18. Yamazaki, T.; Kirchmair, A.; Sato, A.; Buqué, A.; Rybstein, M.; Petroni, G.; Bloy, N.; Finotello, F.; Stafford, L.; Navarro Manzano, E.; et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. *Nat. Immunol.* 2020, 21, 1160–1171. [CrossRef]

19. Yatim, N.; Jusforgues-Saklani, H.; Orozco, S.; Schulz, O.; Barreira da Silva, R.; Reis e Sousa, C.; Green, D.R.; Oberst, A.; Albert, M.L. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells. *Science* 2015, 350, 328–334. [CrossRef]

20. Bakhiet, M. Peripheral blood mitochondrial DNA copy number as a novel potential biomarker for diabetic nephropathy in type 2 diabetes patients. *Exp. Ther. Med.* 2018, 16, 1483–1492. [CrossRef]

21. Taunk, N.K.; et al. Chromosomal instability drives metastasis through a cytosolic DNA response. *Nature* 2018, 553, 467–472. [CrossRef]

22. Cheng, Y.; Sun, Y.; Wang, H.; Yan, Y.; Ding, C.; Sun, J. Chicken STING Mediates Activation of the IFN Gene Independently of the RIG-I Gene. *J. Immunol.* 2015, 195, 3922–3936. [CrossRef]

23. Zhong, B.; Yang, Y.; Li, S.; Wang, Y.Y.; Li, Y.; Diao, F.; Lei, C.; He, X.; Zhang, L.; Tien, P.; et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. *Immunity* 2008, 29, 538–550. [CrossRef]

24. Barber, G.N. STING: Infection, inflammation and cancer. *Nat. Rev. Immunol.* 2015, 15, 760–770. [CrossRef]

25. Burdette, D.L.; Vance, R.E. STING and the innate immune response to nucleic acids in the cytosol. *Nat. Immunol.* 2013, 14, 19–26. [CrossRef]

26. Dhanwani, R.; Takahashi, M.; Sharma, S. Cytosolic sensing of immuno-stimulatory DNA, the enemy within. *Curr. Opin. Immunol.* 2018, 50, 82–87. [CrossRef]

27. Chung, K.W.; Dhillon, P.; Huang, S.; Sheng, X.; Shrestha, R.; Qiu, C.; Kaufman, B.A.; Park, J.; Pei, L.; Baur, J.; et al. Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis. *Cell Metab.* 2019, 30, 784–799.e5. [CrossRef]

28. Mitrofanova, A.; Fontanella, A.; Tolerico, M.; Mallela, S.K.; Molina, J.; Kim, J.J.; Burke, G.; Merscher, S.; Fornoni, A. STING activation causes proteinuria in mice and contributes to glomerular disease. *Kidney Int. Rep.* 2022, 7, S155–S156. [CrossRef]

29. Mitrofanova, A.; Fontanella, A.; Tolerico, M.; Mallela, S.; Molina, J.; Zuo, Y.; Boulina, M.; Kim, J.-J.; Varona Santos, J.; Ge, M.; et al. Activation of Stimulator of Interferon Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases. *J. Am. Soc. Nephrol.* 2022, 33. [CrossRef]

30. Khedr, S.; Dissanayake, L.V.; Palygin, O.; Staruschenko, A. Potential Role of cGAS-STING Pathway in the Induction of Diabetic Kidney Disease. *FASEB J.* 2020, 34, 1. [CrossRef]

31. Sharma, K.; Karl, B.; Mathew, A.V.; Gangoiti, J.A.; Wassel, C.L.; Saito, R.; Pu, M.; Sharma, S.; You, Y.H.; Wang, L.; et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. *J. Am. Soc. Nephrol.* JASN 2013, 24, 1901–1912. [CrossRef]

32. Al-Kafaji, G.; Aljadaan, A.; Kamal, A.; Bakhiet, M. Peripheral blood mitochondrial DNA copy number as a novel potential biomarker for diabetic nephropathy in type 2 diabetes patients. *Exp. Ther. Med.* 2018, 16, 1483–1492. [CrossRef]

33. Cao, H.; Wu, J.; Luo, J.; Chen, X.; Yang, J.; Fang, L. Urinary mitochondrial DNA: A potential early biomarker of diabetic nephropathy. *Diabetes Metab. Res. Rev.* 2019, 35, e3131. [CrossRef]
34. Jiang, H.; Shao, X.; Jia, S.; Qu, L.; Weng, C.; Shen, X.; Wang, Y.; Huang, H.; Wang, Y.; Wang, C.; et al. The Mitochondria-Targeted Metabolic Tubulostat Inhibits Inflammatory Activation in Diabetic Kidney Disease. *Cell Physiol. Biochem.* 2019, 52, 156–171. [CrossRef]

35. Qi, H.; Casalena, G.; Shi, S.; Yu, L.; Ebeffors, K.; Sun, Y.; Zhang, W.; D’Agati, V.; Schindlovits, D.; Haraldsson, B.; et al. Glomerular Endothelial Mitochondrial Dysfunction Is Essential and Characteristic of Diabetic Kidney Disease Susceptibility. *Diabetes* 2017, 66, 763–778. [CrossRef]

36. Kakimoto, M.; Inoguchi, T.; Sonta, T.; Yu, H.Y.; Imamura, M.; Etoh, T.; Hashimoto, T.; Nawata, H. Accumulation of 8-Hydroxy-2′-Deoxyguanosine and Mitochondrial DNA Deletion in Kidney of Diabetic Rats. *Diabetes* 2002, 51, 1588–1595. [CrossRef]

37. Akhtar, S.; Siragy, H.M. Pro-renin receptor suppresses mitochondrial biogenesis and function via AMPK/SIRT-1/ PGC-1α pathway in diabetic kidney. *PLoS ONE* 2019, 14, e0225728. [CrossRef]

38. Ma, X.M.; Geng, K.; Law, B.Y.-K.; Wang, P.; Pu, Y.L.; Chen, Q.; Xu, H.W.; Tan, X.Z.; Jiang, Z.Z.; Xu, Y. Lipotoxicity-induced mtDNA release promotes diabetic cardiomyopathy by activating the GNAS-STING pathway in obesity-related diabetes. *Cell Biol. Toxicol.* 2022. [CrossRef]

39. Hur, S. Double-Stranded RNA Sensors and Modulators in Innate Immunity. *Annu. Rev. Immunol.* 2019, 37, 349–375. [CrossRef] [PubMed]

40. Dhir, A.; Dhir, S.; Borovsky, L.S.; Jimenez, L.; Teitel, M.; Rötig, A.; Crow, Y.J.; Rice, G.I.; Duffy, D.; Tamby, C.; et al. Mitochondrial double-stranded RNA triggers antiviral signalling in humans. *Nature* 2018, 560, 238–242. [CrossRef] [PubMed]

41. Tiganu, M.; Vargas, D.C.; Tremblay-Belzile, S.; Fu, Y.; Sfeir, A. Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. *Nature* 2021, 591, 477–481. [CrossRef]

42. Di Mauro, S.; Scamporrino, A.; Filippello, A.; Di Marco, M.; Di Martino, M.T.; Scionti, F.; Di Pino, A.; Scicali, R.; Malaguarnera, R.; Purrello, F.; et al. Mitochondrial RNAs as Potential Biomarkers of Functional Impairment in Diabetic Pathologies. *Int. J. Mol. Sci.* 2022, 23, 8198. [CrossRef]

43. Salem, R.M.; Todd, J.N.; Sandholm, N.; Cole, J.B.; Chen, W.-M.; Andrews, D.; Pezzolesi, M.G.; McKeigue, P.M.; Hiraki, L.T.; Qiu, C.; et al. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. *J. Am. Soc. Nephrol.* 2019, 30, 2000–2016. [CrossRef]

44. Muruve, D.A.; Petrelli, V.; Zais, A.K.; White, L.R.; Clark, S.A.; Ross, P.J.; Parks, R.J.; Tschopp, J. The inflammasome recognizes cytotoxic microbial and host DNA and triggers an innate immune response. *Nature* 2008, 452, 103–107. [CrossRef]

45. Shimada, K.; Tachitra, V.; Karlin, J.; Dagvadorj, J.; Chiba, N.; Chen, S.; Ramanujan, V.K.; Wolf, A.J.; Verghese, L.; Ocius, D.M.; et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* 2012, 36, 401–414. [CrossRef]

46. Nakahira, K.; Haspel, J.A.; Rathinam, V.A.; Lee, S.J.; Dolinay, T.; Nawata, H. Accumulation of 8-Hydroxy-2′-Deoxyguanosine and Mitochondrial DNA Deletion in Kidney of Diabetic Rats. *Diabetes* 2002, 51, 1588–1595. [CrossRef]

47. Saxena, G.; Chen, J.; Shalev, A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. *J. Biol. Chem.* 2010, 285, 3997–4005. [CrossRef] [PubMed]

48. Bauerfeind, F.; Bartok, E.; Rieger, A.; Franchi, L.; Hauler, G.; Hornung, V. Cutting edge: Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. *J. Immunol.* 2011, 187, 613–617. [CrossRef] [PubMed]

49. Billingham, L.K.; Stoolman, J.S.; Vasan, K.; Rodríguez, A.E.; Poor, T.A.; Szibor, M.; Jacobs, H.T.; Reczek, C.R.; Rashidi, A.; Zhang, P.; et al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. *Nature* 2011, 477–481. [CrossRef]

50. Zhong, Z.; Liang, S.; Sanchez-Lopez, E.; He, F.; Shalapour, S.; Lin, X.J.; Wong, J.; Ding, S.; Seki, E.; Schnabl, B.; et al. New mitochondrial DNA releases NLRP3 inflammasome activation. *Nature* 2012, 560, 198–203. [CrossRef]

51. Latz, E.; Xiao, T.S.; Stutz, A. Activation and regulation of the inflammasomes. *Nat. Rev. Immunol.* 2013, 13, 397–411. [CrossRef] [PubMed]

52. Dang, E.V.; McDonald, J.G.; Russell, D.W.; Cyster, J.G. Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation. *Cell* 2017, 171, 1057–1071.e11. [CrossRef] [PubMed]

53. Shahzad, K.; Bock, F.; Dong, W.; Wang, H.; Kopf, S.; Kohli, S.; Al-Dabe, M.M.; Ranjan, S.; Wolter, J.; Wacker, C.; et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. *Kidney Int.* 2015, 87, 74–84. [CrossRef] [PubMed]

54. Birnbaum, Y.; Bajaj, M.; Yang, H.C.; Ye, Y. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. *Cardiovasc. Drugs Ther.* 2018, 32, 135–145. [CrossRef] [PubMed]

55. Carlos, D.; Costa, F.R.; Pereira, C.A.; Rocha, F.A.; Yaochite, J.N.; Oliveira, G.G.; Carneiro, F.S.; Tostes, R.C.; Ramos, S.G.; Zamboni, D.S.; et al. Mitochondrial DNA Activates the NLRP3 Inflammasome and Predisposes to Type 1 Diabetes in Murine Model. *Front. Immunol.* 2017, 8, 164. [CrossRef] [PubMed]

56. Pereira, C.A.; Carlos, D.; Ferreira, N.S.; Silva, J.F.; Zanotto, C.Z.; Zamboni, D.S.; Garcia, V.D.; Ventura, D.F.; Silva, J.S.; Tostes, R.C. Mitochondrial DNA Promotes NLRP3 Inflammasome Activation and Contributes to Endothelial Dysfunction and Inflammation in Type 1 Diabetes. *Front. Physiol.* 2019, 10, 1597. [CrossRef]

57. Huang, Y.; Zhou, J.H.; Zhang, H.; Canfran-Duque, A.; Singh, A.K.; Perry, R.J.; Shulman, G.I.; Fernandez-Hernando, C.; Min, W. Brown adipose TRX2 deficiency activates mtDNA-NLRP3 to impair thermogenesis and protect against diet-induced insulin resistance. *J. Clin. Investig.* 2022, 132, e148852. [CrossRef]
58. Nam, B.Y.; Jhee, J.H.; Park, J.; Kim, S.; Kim, G.; Park, J.T.; Yoo, T.-H.; Kang, S.-W.; Yu, J.-W.; Han, S.H. PGC-1α inhibits the NLRP3 inflammasome via preserving mitochondrial viability to protect kidney fibrosis. *Cell Death Dis.* 2022, 13, 31. [CrossRef]

59. Shahzad, K.; Fatima, S.; Khawaja, H.; Elwakiel, A.; Gadi, I.; Ambreen, S.; Zimmermann, S.; Mertens, P.R.; Biemann, R.; Isermann, B. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. *Kidney Int.* 2022, 102, 766–779. [CrossRef]

60. Östergaard, J.A.; Iha, J.C.; Sharma, A.; Dai, A.; Choi, J.S.Y.; de Haan, J.B.; Cooper, M.E.; Jandeleit-Dahm, K. Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease. *Clin. Sci.* 2022, 136, 167–180. [CrossRef]

61. Knauf, F.; Asplin, J.R.; Granja, I.; Schmidt, I.M.; Moeckel, G.W.; David, R.J.; Flavell, R.A.; Aronson, P.S. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxate nephopathy. *Kidney Int.* 2013, 84, 895–901. [CrossRef]

62. Bae, J.H.; Jo, S.I.; Kim, S.J.; Lee, J.M.; Jeong, J.H.; Kang, J.S.; Cho, N.J.; Kim, S.S.; Lee, E.Y.; Moon, J.S. Circulating Cell-Free mtDNA Contributes to A1M2 Inflammasome-Mediated Chronic Inflammation in Patients with Type 2 Diabetes. *Cells* 2019, 8, 328. [CrossRef] [PubMed]

63. Zhang, Q.; Raof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating mitochondrial DNA induces inflammation and increases TLR9/NF-κB expression in lung tissue. *Int. J. Mol. Med.* 2014, 33, 817–824. [CrossRef] [PubMed]

64. Tian, J.; Aivalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drubic, S.; Golenbock, D.; Siros, C.; et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat. Immunol.* 2007, 8, 487–496. [CrossRef] [PubMed]

65. Zhang, J.Z.; Liu, Z.; Liu, J.; Ren, J.X.; Sun, T.S. Mitochondrial DNA induces inflammation and increases TLR9/NF-κB expression in renal disease. *Curr. Opin. Pharmacol.* 2010, 10, 104–107. [CrossRef] [PubMed]

66. Zhang, Q.Z.; Liu, Z.; Liu, J.; Ren, J.X.; Sun, T.S. Mitochondrial DNA induces inflammation and increases TLR9/NF-κB expression in renal tissue. *Int. J. Mol. Med.* 2014, 33, 817–824. [CrossRef] [PubMed]

67. Oka, T.; Hikoso, S.; Yamaguchi, O.; Takeda, T.; Tama, T.; Oyabu, J.; Nakamura, H.; Nishida, K.; et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. *Nature* 2012, 485, 251–255. [CrossRef]

68. Papadimitraki, E.; Tzardi, M.; Bertsias, G.; Sotsiou, E.; Boumpas, D. Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: Implications for the amplification of the inflammatory response. *Lupus* 2009, 18, 831–835. [CrossRef]

69. Machida, H.; Ito, S.; Hirose, T.; Takeshita, F.; Oshiro, H.; Nakamura, T.; Mori, M.; Inayama, Y.; Yan, K.; Kobayashi, N.; et al. Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. *Nephrol. Dial. Transplant.* 2010, 25, 2430–2537. [CrossRef]

70. Batsford, S.; Duermueller, U.; Seemayer, C.; Mueller, C.; Hopfer, H.; Mihatsch, M. Protein level expression of Toll-like receptors 2, 4 and 9 in renal disease. *Nephrol. Dial. Transplant.* 2011, 26, 1413–1416. [CrossRef]

71. Frieri, M.; Samih, M.A.; Dzhindzhikhashvili, M.; Liu, H.; Balsam, L.; Rubinstein, S. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. *J. Nephrol.* 2012, 25, 1041–1046. [CrossRef]

72. Bao, W.; Xia, H.; Liang, Y.; Ye, Y.; Lu, Y.; Xu, X.; Duan, A.; He, J.; Chen, Z.; Wu, Y.; et al. Toll-like Receptor 9 Can be Activated by Endogenous Mitochondrial DNA to Induce Podocyte Apoptosis. *Sci. Rep.* 2016, 6, 22579. [CrossRef] [PubMed]

73. Sureshbabu, A.; Patino, E.; Ma, K.C.; Laursen, K.; Finkelsztein, E.J.; Akchurin, O.; Muthukumar, T.; Ryter, S.W.; Gudas, L.; Choi, A.M.K.; et al. RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction. *JCI Insight* 2018, 3, e98411. [CrossRef] [PubMed]

74. Mitrofanova, A.; Fontanella, A.M.; Mersch, S.; Fornoni, A. Lipid deposition and metaplasma in diabetic kidney disease. *Curr. Opin. Pharmacol.* 2020, 55, 60–72. [CrossRef] [PubMed]

75. Brennan, E.P.; Mohan, M.; McClelland, A.; Tikelis, C.; Zieman, M.; Kaspi, A.; Gray, S.P.; Pickering, R.; Tan, S.M.; Ali-Shah, S.T.; et al. Lipoxins Regulate the Early Response-1 Network and Reverse Diabetic Kidney Disease. *Front. Physiol.* 2020, 11, 84. [CrossRef]

76. Woroniecka, K.I.; Park, A.S.; Mohtat, D.; Thomas, D.B.; Pullman, J.M.; Susztak, K. Transcriptome analysis of human diabetic kidney disease. *Kidney Int.* 2014, 86, 1041–1046. [CrossRef]

77. Zhang, H.; Sun, S.C. NF-κB in inflammation and renal diseases. *Cell Biosci.* 2015, 5, 63. [CrossRef]

78. Sun, S.C. The noncanonical NF-κB pathway. *Immunol. Rev.* 2012, 246, 125–140. [CrossRef]

79. Giampazolias, E.; Zunino, B.; Dhayade, S.; Bock, F.; Cloix, C.; Roca, A.; Lopez, J.; Ichim, G.; Proïcs, E.; et al. Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. *Nat. Cell Biol.* 2017, 19, 1116–1129. [CrossRef]

80. Foresto-Neto, O.; Albino, A.H.; Arias, S.C.A.; Faustino, V.D.; Zambom, F.F.F.; Cenedese, M.A.; Elias, R.M.; Malheiros, D.; Camara, N.O.S.; Fujihara, C.K.; et al. NF-κB System Is Chronically Activated and Promotes Glomerular Injury in Experimental Type 1 Diabetic Kidney Disease. *Front. Physiol.* 2020, 11, 84. [CrossRef]

81. Lee, F.T.; Cao, Z.; Long, D.M.; Panagiotopoulos, S.; Jerums, G.; Cooper, M.E.; Forbes, J.M. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. *J. Am. Soc. Nephrol.* 2004, 15, 2139–2151. [CrossRef] [PubMed]

82. Mezzano, S.; Aros, C.; Drogueaut, A.; Burgos, M.E.; Ardiles, L.; Flores, C.; Schneider, H.; Ruiz-Ortega, M.; Egido, J. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. *Nephrol. Dial. Transplant.* 2004, 19, 2505–2512. [CrossRef] [PubMed]
83. Lin, M.; Yiu, W.H.; Wu, H.J.; Chan, L.Y.; Leung, J.C.; Au, W.S.; Chan, K.W.; Lai, K.N.; Tang, S.C. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. *J. Am. Soc. Nephrol.* [JASN] 2012, 23, 86–102. [CrossRef] [PubMed]

84. Wei, M.; Li, Z.; Xiao, L.; Yang, Z. Effects of ROS-relative NF-κB signaling on high glucose-induced TLR4 and MCP-1 expression in podocyte injury. *J. Mol. Immunol.* 2015, 68, 261–271. [CrossRef] [PubMed]

85. Bottero, V.; Busuttil, V.; Loubat, A.; Magné, N.; Fischel, J.L.; Milano, G.; Peyron, J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. *Cancer Res.* 2001, 61, 7785–7791. [PubMed]

86. Cogswell, P.C.; Kashatus, D.F.; Keifer, J.A.; Guttridge, D.C.; Reuther, J.Y.; Bristow, C.; Roy, S.; Nicholson, D.W.; Baldwin, A.S., Jr. NF-kappaB and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-κB. *J. Biol. Chem.* 2003, 278, 2963–2968. [CrossRef]

87. Guseva, N.V.; Taghiyev, A.F.; Sturm, M.T.; Rokhlin, O.W.; Cohen, M.B. Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines. *Mol. Cancer Res.* 2004, 2, 574–584. [CrossRef] [PubMed]

88. Bottero, V.; Busuttil, V.; Loubat, A.; Magné, N.; Fischel, J.L.; Milano, G.; Peyron, J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. *Cancer Res.* 2001, 61, 7785–7791. [PubMed]

89. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* 2009, 324, 1029–1033. [CrossRef] [PubMed]

90. Pascara, A.-M.G.; Sekeris, C.E. Nuclear receptors and other nuclear transcription factors in mitochondria: Regulatory molecules in a new environment. *Biochim. Biophys. Acta (BBA)-Mol. Cell Res.* 2008, 1783, 1–11. [CrossRef]

91. Johnson, R.F.; Witzel, I.-I.; Perkins, N.D. p53-Dependent Regulation of Mitochondrial Energy Production by the RelA Subunit of NF-κB. *Cancer Res.* 2011, 71, 5588–5597. [CrossRef] [PubMed]

92. Domizio, J.D.; Gulen, M.F.; Saidoune, F.; Thacker, V.V.; Yatim, A.; Sharma, K.; Schaller, M.; Conrad, C.; et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. *Nature 2022*, 603, 145–151. [CrossRef] [PubMed]

93. Kim, J.; Gupta, R.; Blanco, L.P.; Yang, S.; Shteinier-Kuzmine, A.; Wang, K.; Zhu, J.; Yoon, H.E.; Wang, X.; Kerkhofs, M.; et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. *Science 2019*, 366, 1531–1536. [CrossRef] [PubMed]

94. Domizio, J.D.; Gulen, M.F.; Saidoune, F.; Thacker, V.V.; Yatim, A.; Sharma, K.; Nass, T.; Guenova, E.; Schaller, M.; Conrad, C.; et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. *Nature 2022*, 603, 145–151. [CrossRef] [PubMed]

95. Johnson, R.F.; Witzel, I.-I.; Perkins, N.D. p53-Dependent Regulation of Mitochondrial Energy Production by the RelA Subunit of NF-κB. *Cancer Res.* 2011, 71, 5588–5597. [CrossRef] [PubMed]

96. Domizio, J.D.; Gulen, M.F.; Saidoune, F.; Thacker, V.V.; Yatim, A.; Sharma, K.; Schaller, M.; Conrad, C.; et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. *Nature 2022*, 603, 145–151. [CrossRef] [PubMed]

97. Kim, J.; Gupta, R.; Blanco, L.P.; Yang, S.; Shteinier-Kuzmine, A.; Wang, K.; Zhu, J.; Yoon, H.E.; Wang, X.; Kerkhofs, M.; et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. *Science 2019*, 366, 1531–1536. [CrossRef] [PubMed]

98. Bottero, V.; Busuttil, V.; Loubat, A.; Magné, N.; Fischel, J.L.; Milano, G.; Peyron, J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. *Cancer Res.* 2001, 61, 7785–7791. [PubMed]

99. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* 2009, 324, 1029–1033. [CrossRef] [PubMed]

100. Pascara, A.-M.G.; Sekeris, C.E. Nuclear receptors and other nuclear transcription factors in mitochondria: Regulatory molecules in a new environment. *Biochim. Biophys. Acta (BBA)-Mol. Cell Res.* 2008, 1783, 1–11. [CrossRef]

101. Johnson, R.F.; Witzel, I.-I.; Perkins, N.D. p53-Dependent Regulation of Mitochondrial Energy Production by the RelA Subunit of NF-κB. *Cancer Res.* 2011, 71, 5588–5597. [CrossRef] [PubMed]

102. Domizio, J.D.; Gulen, M.F.; Saidoune, F.; Thacker, V.V.; Yatim, A.; Sharma, K.; Nass, T.; Guenova, E.; Schaller, M.; Conrad, C.; et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. *Nature 2022*, 603, 145–151. [CrossRef] [PubMed]

103. Sun, J.; Mao, L.Q.; Polonsky, K.S.; Ren, D.C. Pancreatic β-Cell Death due to Pdx-1 Deficiency Requires Multi-BH Domain Protein Bax but Not Bak. *J. Biol. Chem.* 2016, 291, 13529–13534. [CrossRef] [PubMed]

104. Lei, J.; Zhao, L.; Zhang, Y.; Wu, Y.; Liu, Y. High Glucose-Induced Podocyte Injury Involves Activation of Mammalian Target of Rapamycin (mTOR)-Induced Endoplasmic Reticulum (ER) Stress. *Cell. Physiol. Biochem.* 2018, 45, 2431–2443. [CrossRef]

105. Liu, X.; Jiang, L.; Li, Y.; Huang, Y.; Hu, X.; Zhu, W.; Wang, X.; Wu, Y.; Meng, X.; Qi, X. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease. *Acta Pharmacol. Sin.* 2022, 43, 96–110. [CrossRef]

106. Lecocq, J.; Ballou, C.E. On the Structure Of Cardiolipin. *Biochemistry* 1964, 3, 976–980. [CrossRef]

107. Arnarez, C.; Marrink, S.J.; Periole, X. Identification of cardiolipin binding sites on cytochrome c oxidase at the entrance of proton channels. *Sci. Rep.* 2013, 3, 1263. [CrossRef]

108. Tyurina, Y.Y.; Domingues, R.M.; Tyurin, V.A.; Maciel, E.; Domingues, P.; Amosco, A.A.; Bayir, H.; Kagan, V.E. Characterization of cardiolipins and their oxidation products by LC-MS analysis. *Chem. Phys. Lipids* 2014, 179, 3–10. [CrossRef]
109. Chu, C.T.; Ji, J.; Dagda, R.K.; Jiang, J.F.; Tyurina, Y.Y.; Kapralov, A.A.; Tyurin, V.A.; Yanamala, N.; Shrivastava, L.H.; Mohammadyani, D.; et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 2013, 15, 1197–1205. [CrossRef]

110. Chao, H.; Lin, C.; Zuo, Q.; Liu, Y.; Xiao, M.; Xu, X.; Li, Z.; Bao, Z.; Chen, H.; You, Y.; et al. Cardiolipin-Dependent Mitophagy Guides Outcome After Traumatic Brain Injury. J. Neurosci. 2019, 39, 1930–1943. [CrossRef]

111. Iriondo, M.N.; Etxaniz, A.; Varela, Y.R.; Hervás, J.H.; Montes, L.R.; Góñi, F.M.; Alonso, A. LC3 subfamily in cardiolipin-mediated mitophagy: A comparison of the LC3A, LC3B and LC3C homologs. bioRxiv 2020. [CrossRef] [PubMed]

112. Leslie, D.S.; Dascher, C.C.; Cembrola, K.; Townes, M.A.; Hava, D.L.; Hugendubler, L.C.; Mueller, E.; Fox, L.; Roura-Mir, C.; Moody, D.B.; et al. Serum lipids regulate dendritic cell CD1 expression and function. Immunology 2008, 125, 289–301. [CrossRef] [PubMed]

113. Luévano-Martínez, L.A.; Forni, M.F.; dos Santos, V.T.; Souza-Pinto, N.C.; Kowaltowski, A.J. Cardiolipin is a key determinant for mtDNA stability and segregation during mitochondrial stress. Biochim. Biophys. Acta 2015, 1847, 587–598. [CrossRef] [PubMed]

114. Chen, L.; Dong, J.; Liao, S.; Wang, S.; Wu, Z.; Zuo, M.; Liu, B.; Yan, C.; Chen, Y.; He, H.; et al. Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury. Hepatology 2022, 76, 1389–1408. [CrossRef] [PubMed]

115. Miyamoto, S.; Zhang, G.; Hall, D.; Oates, P.J.; Maity, S.; Adesh, M.; Han, X.; Sharma, K. Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects db/db mice against progression of diabetic kidney disease. J. Biol. Chem. 2020, 295, 7249–7260. [CrossRef]

116. Tan, S.M.; Ziemann, M.; Thallas-Bonke, V.; Snelson, M.; Kumar, V.; Laskowski, A.; Nguyen, T.V.; Huynh, K.; Clarke, M.; Libianto, R.; et al. Complement C5a induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Activity. Diabetes 2020, 69, 83–98. [CrossRef]

117. Gladkova, C.; Maslen, S.L.; Skehel, J.M.; Komander, D. Mechanism of parkin activation by PINK1. Nature 2018, 559, 410–414. [CrossRef]

118. Wu, H.; Xue, D.; Chen, G.; Han, Z.; Huang, L.; Zhu, C.; Wang, X.; Jin, H.; Wang, J.; Zhu, Y.; et al. The BCL2L1 and PGAM5 axis regulates mitochondrial function. Autophagy 2014, 10, 1712–1725. [CrossRef]

119. Chen, M.; Chen, Z.; Wang, Y.; Tan, Z.; Zhu, C.; Li, Y.; Han, Z.; Chen, L.; Gao, R.; Liu, L.; et al. Mitophagy receptor FUNDC1 regulates mitochondrial dynamics and mitophagy. Autophagy 2016, 12, 689–702. [CrossRef]

120. Zhang, J.; Neya, P.A. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Dis. 2019, 10, 6355. [CrossRef] [PubMed]

121. Rogov, V.V.; Suzuki, H.; Marinikovich, M.; Lang, V.; Kato, R.; Kawasaki, M.; Buljubašić, M.; Šprung, M.; Rogova, N.; Wakisaka, S.; et al. Phosphorylation of the mitochondrial autophagy receptor Nix enhances its interaction with LC3 proteins. Sci. Rep. 2017, 7, 1131. [CrossRef]

122. Huang, C.; Zhang, Y.; Kelly, D.J.; Tan, C.Y.; Gill, A.; Cheng, D.; Braet, F.; Park, J.S.; Sue, C.M.; Pollock, C.A.; et al. Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway. Sci. Rep. 2016, 6, 29196. [CrossRef] [PubMed]

123. Chen, K.; Dai, H.; Yuan, J.; Chen, J.; Lin, L.; Zhang, W.; Wang, L.; Zhang, J.; Li, K.; He, Y. Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy. Cell Death Dis. 2019, 10, 1197–1205. [CrossRef] [PubMed]

124. Feng, J.; Lu, C.; Dai, Q.; Sheng, J.; Xu, M. SIRT3 Facilitates Amniotic Fluid Stem Cells to Repair Diabetic Nephropathy Through Protecting Mitochondrial Homeostasis by Modulation of Mitophagy. Cell Physiol. Biochem. 2018, 46, 1508–1524. [CrossRef] [PubMed]

125. Chen, K.; Chen, J.; Wang, L.; Yang, J.; Xiao, F.; Wang, X.; Yuan, J.; Wang, L.; He, Y. Parkin ubiquitinates GATA4 and attenuates the GATA4/GAS1 signaling and detrimental effects on diabetic nephropathy. FASEB J. 2020, 34, 8858–8875. [CrossRef]

126. Li, W.; Du, M.; Wang, Q.; Ma, X.; Wu, L.; Guo, F.; Ji, H.; Huang, F.; Qin, G. FoxO1 Promotes Mitophagy in the Podocytes of Diabetic Male Mice via the PINK1/Parkin Pathway. Endocrinology 2017, 158, 2155–2167. [CrossRef]

127. Zhou, D.; Zhou, M.; Wang, Z.; Fu, Y.; Jia, M.; Wang, X.; Liu, M.; Zhang, Y.; Sun, Y.; Zhou, Y.; et al. Progranulin alleviates podocyte injury via regulating CAMKK/AMPK-mediated autophagy under diabetic conditions. J. Mol. Med. 2019, 125, 1507–1520. [CrossRef]

128. Sun, J.; Zhu, H.; Wang, X.; Gao, Q.; Li, Z.; Huang, H. CoQ10 ameliorates mitochondrial dysfunction in diabetic nephropathy through mitophagy. J. Endocrinol. 2019, 209, 445–465. [CrossRef]

129. Li, X.Y.; Wang, S.S.; Han, Z.; Han, F.; Chang, Y.P.; Yang, Y.; Xue, M.; Sun, B.; Chen, L.M. Tripotide Restores Autophagy to Alleviate Diabetic Renal Fibrosis through the miR-141-3p/PTEN/Akt/mTOR Pathway. Mol. Ther. Nucleic Acids 2017, 9, 48–56. [CrossRef]

130. Liu, X.; Wang, W.; Song, G.; Wei, X.; Zeng, Y.; Han, P.; Wang, D.; Shao, M.; Wu, J.; Sun, H.; et al. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network. PLoS ONE 2017, 12, e0182558. [CrossRef]

131. Liu, X.; Lu, J.; Liu, S.; Huang, D.; Chen, M.; Xiong, G.; Li, S. Huangqi-Danshen decoction alleviates diabetic nephropathy in db/db mice by inhibiting PINK1/Parkin-mediated mitophagy. Am. J. Transl. Res. 2020, 12, 989–998. [CrossRef]

132. Lee, E.-J.; Kang, M.-K.; Kim, Y.-H.; Kim, D.Y.; Oh, H.; Kim, S.-I.; Oh, S.Y.; Kang, Y.-H. Dietary Chrysin Suppresses Formation of Actin Cytoskeleton and Focal Adhesion in AGE-Exposed Mesangial Cells and Diabetic Kidney: Role of Autophagy. Nutrients 2019, 11, 127. [CrossRef] [PubMed]
133. Wang, K.; Zheng, X.; Pan, Z.; Yao, W.; Gao, X.; Wang, X.; Ding, X. Icarin Prevents Extracellular Matrix Accumulation and Ameliorates Experimental Diabetic Kidney Disease by Inhibiting Oxidative Stress via GPER Mediated p62-Dependent Keap1 Degradation and Nrf2 Activation. *Front. Cell Dev. Biol.* **2020**, *8*, 559. [CrossRef] [PubMed]

134. Gao, C.; Fan, F.; Chen, J.; Long, Y.; Tang, S.; Jiang, C.; Xu, Y. FBW7 Regulates the Autophagy Signal in Mesangial Cells Induced by High Glucose. *BioMed Res. Int.* **2019**, *2019*, 6061594. [CrossRef] [PubMed]

135. Lu, X.; Fan, Q.; Xu, L.; Li, L.; Yue, Y.; Xu, Y.; Su, Y.; Zhang, D.; Wang, L. Ursolic acid attenuates diabetic mesangial cell injury through the up-regulation of autophagy via miRNA-21/PTEN/Akt/mTOR suppression. *PloS ONE* **2015**, *10*, e0117400. [CrossRef] [PubMed]

136. Wen, D.; Tan, R.Z.; Zhao, C.Y.; Li, J.C.; Zhong, X.; Diao, H.; Lin, X.; Duan, D.D.; Fan, J.M.; Xie, X.S.; et al. Astragalus mongholicus Bunge and Panax notoginseng (Burkill) F.H. Chen Formula for Renal Injury in Diabetic Nephropathy-In Vivo and In Vitro Evidence for Autophagy Regulation. *Front. Pharmacol.* **2020**, *11*, 732. [CrossRef] [PubMed]

137. Han, Y.-C.; Tang, S.-Q.; Liu, Y.-T.; Li, A.-M.; Zhan, M.; Yang, M.; Song, N.; Zhang, W.; Wu, X.-Q.; Peng, C.-H.; et al. AMPK agonist alleviates renal tubulointerstitial fibrosis by activating mitophagy in high fat and streptozotocin induced diabetic mice. *Cell Death Dis.* **2021**, *12*, 925. [CrossRef] [PubMed]

138. Xiao, L.; Xu, X.; Zhang, F.; Wang, M.; Xu, Y.; Tang, D.; Wang, J.; Qin, Y.; Liu, Y.; Tang, C.; et al. The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PI3K1. *Redox Biol.* **2017**, *11*, 297–311. [CrossRef]

139. Jiang, X.S.; Chen, X.M.; Hua, W.; He, J.L.; Liu, T.; Li, X.J.; Wan, J.M.; Gan, H.; Du, X.G. PINK1/Parkin mediated mitophagy ameliorates palmitic acid-induced apoptosis through reducing mitochondrial production in podocytes. *Biochem. Biophys. Res. Commun.* **2020**, *525*, 954–961. [CrossRef]

140. Bergsbaken, T.; Cookson, B.T. Macrophage activation redirects yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. *PloS Pathog.* **2007**, *3*, e161. [CrossRef]

141. Shi, J.; Zhao, Y.; Wang, K.; Shi, X.; Wang, Y.; Huang, H.; Zhuang, Y.; Cai, T.; Wang, F.; Shao, F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature 2015*, *526*, 660–665. [CrossRef]

142. Kelley, N.; Jeltema, D.; Duan, Y.; He, Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. *Int. J. Mol. Sci.* **2019**, *20*, 3328. [CrossRef] [PubMed]

143. Yu, Z.W.; Zhang, J.; Li, X.; Wang, Y.; Fu, Y.H.; Gao, X.Y. A new research hot spot: The role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications. *Life Sci. 2020*, *240*, 117138. [CrossRef] [PubMed]

144. Cheng, Q.; Pan, J.; Zhou, Z.-I.; Yin, F.; Xie, H.-y.; Chen, P.-p.; Li, J.-y.; Zheng, P.-q.; Zhou, L.; Zhang, W.; et al. Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy. *Acta Pharmacol. Sin.* **2021**, *42*, 954–963. [CrossRef] [PubMed]

145. Gao, Y.; Ma, Y.; Xie, D.; Jiang, H. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model. *Int. Immunopharmacol.* **2022**, *107*, 108711. [CrossRef]

146. Wang, H.; Lv, D.; Jiang, S.; Hou, Q.; Zhang, L.; Li, S.; Zhu, X.; Xu, X.; Wen, J.; Zeng, C.; et al. Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction. *Cell Death Dis.* **2022**, *13*, 281. [CrossRef] [PubMed]

147. Rogers, C.; Erkes, D.A.; Nardone, A.; Aplin, A.E.; Fernandes-Alnemri, T.; Alnemri, E.S. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Acta Pharmacol. Sin.* **2021**, *20*, 925. [CrossRef] [PubMed]

148. Rogers, C.; Fernandes-Alnemri, T.; Mayes, L.; Alnemri, D.; Cingolani, G.; Alnemri, E.S. Cleavage of DFFA5 by caspase-3 during apoptosis mediates secondary necrotic/pyroptotic cell death. *Nat. Commun.* **2017**, *8*, 14128. [CrossRef] [PubMed]

149. Wang, Y.; Gao, W.; Shi, X.; Ding, J.; Liu, W.; He, H.; Wang, K.; Shao, F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature 2017*, *547*, 99–103. [CrossRef]

150. Wu, W.Y.; Wang, Z.X.; Li, T.S.; Ding, X.Q.; Liu, Z.H.; Yang, J.; Fang, L.; Kong, L.D. SSBI1 drives high fructose-induced glomerular podocyte ferroptosis via activating DNA-PK/cp3 pathway. *Redox Biol.* **2022**, *52*, 102303. [CrossRef]

151. Zhang, Q.; Hu, Y.; Hu, J.-E.; Ding, Y.; Shen, Y.; Xu, H.; Chen, H.; Wu, N. Sp1-mediated upregulation of Prdx6 expression prevents podocyte injury in diabetic nephropathy via mitigation of oxidative stress and ferroptosis. *Life Sci. 2021*, *278*, 119529. [CrossRef]

152. Skonieczna, M.; Cieslar-Pobuda, A.; Saenko, Y.; Foksinski, M.; Olinski, R.; Rzeszowska-Wolny, J.; Wiechec, E. The Impact of DIS1-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation. *Med. Chem. 2017*, *13*, 477–483. [CrossRef] [PubMed]

153. Gao, M.; Yi, J.; Zhu, J.; Minikes, A.M.; Monian, P.; Thompson, C.B.; Jiang, X. Role of Mitochondria in Ferroptosis. *Mol. Cell 2019*, *73*, 354–363.e3. [CrossRef] [PubMed]

154. Wang, Y.; Bi, R.; Quan, F.; Cao, Q.; Lin, Y.; Yue, C.; Cui, X.; Yang, H.; Gao, X.; Zhang, D. Ferroptosis involves in renal tubular cell death in diabetic nephropathy. *Eur. J. Pharmacol.* **2020**, *888*, 173574. [CrossRef] [PubMed]

155. Li, S.; Zheng, L.; Zhang, J.; Liu, X.; Wu, Z. Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy. *Free Radic. Biol. Med.* **2021**, *162*, 435–449. [CrossRef] [PubMed]

156. Kim, S.; Kang, S-W.; Joo, J.; Han, S.H.; Shin, H.; Nam, B.Y.; Park, J.; Yoo, T-H.; Kim, G.; Lee, P.; et al. Characterization of ferroptosis in kidney tubular cell death under diabetic conditions. *Cell Death Dis.* **2021**, *12*, 160. [CrossRef] [PubMed]